Private · Company · Aksjeselskap
Zelluna Immunotherapy AS
816 823 862 ↗Research and experimental development on natural sciences and engineering · NACE 72.100Oslo
↳ Brreg · companies
Activitylast 24 mo
No job-ad activity on file
totals on file · ads-over-time series not yet in Intelligo
Registry changes
Accounts filed · last_annual_accounts_year2024 → 20252026-08-03
Capital change · share_capital2028723.90 → 2704965.22026-08-01
Employees9 → 102026-07-25
Employees9 → 102026-07-17
Field change · registreringsdatoAntallAnsatteNAVAaregisteret2026-02-10 → 2026-07-102026-07-17
NAV + JobStream · company_hiring · Brreg · company_changes
Timelineall sources
accounts_filed: last_annual_accounts_year2024 -> 2025Registry · 2026-08-03
capital_change: share_capital2028723.90 -> 2704965.2Registry · 2026-08-01
employees_change: employees9 -> 10Registry · 2026-07-25
employee_change: antallAnsatte9 -> 10Registry · 2026-07-17
field_change: registreringsdatoAntallAnsatteNAVAaregisteret2026-02-10 -> 2026-07-10Registry · 2026-07-17
field_change: registreringsdatoAntallAnsatteEnhetsregisteret2026-02-12 -> 2026-07-15Registry · 2026-07-17
field_change: kapital{"antallAksjer": 13524826, "belop": 676241.3, "innfortDato": "2025-05-08", "type": "Aksjekapital", "valuta": "NOK"} -> {"antallAksjer": 1...Registry · 2026-05-28
field_change: vedtektsdato2025-03-21 -> 2026-05-20Registry · 2026-05-28
Going concernThe company states available funding supports planned operations into the first quarter of 2027. — to support planned operations into the...Annual report · 2025-12-31
OwnershipIn 2025 Zelluna Immunotherapy AS issued 1,273,480 shares to its parent company Zelluna ASA. — In 2025,elluna ImmunotherapyAS issued1,273,...Annual report · 2025-12-31
Share capitalCapital contributions received but pending registration were presented as share capital not registered and the increases were registered ...Annual report · 2025-12-31
Related partyNo loans or guarantees were outstanding to related parties, board members, management or employees at either year end. — There were no ou...Annual report · 2025-12-31
Related partyUnder the licence agreement with Inven2 the parent company Zelluna ASA issued 227,096 shares to the licensor. — under the licence agreeme...Annual report · 2025-12-31
Related partyZelluna has in-licensed technology from Inven2 AS under agreements amended several times. — several times.Under the agreements Zelluna ha...Annual report · 2025-12-31
ImpairmentAn impairment loss of MNOK 2.3 on licenses was recognised in profit or loss in 2025. — An impairment loss of MNoK 2.3 was recognised in p...Annual report · 2025-12-31
ImpairmentManagement assessed impairment indicators under IAS 36 during 2025. — During 2025 management assessed impairment indicators in accordance...Annual report · 2025-12-31
Staff numbersThe company reports 19.2 full-time equivalents for the financial year. — Antall 19 .2 0 1 arsverk iregnskapsaretAnnual report · 2025-12-31
RemunerationTotal executive remuneration for 2025 was NOK 10 267 thousand, including board fees of NOK 1 500 thousand, with payroll costs of NOK 28 1...Annual report · 2025-12-31
RemunerationThe employee bonus programme in place through 2024 was discontinued and no bonuses were accrued or awarded in 2025. — The Company had a b...Annual report · 2025-12-31
RemunerationFour employees who are members of group management held 450,000 share options at 31 December 2025. — Of these, four employees who are mem...Annual report · 2025-12-31
Deferred taxDeferred tax assets arising from tax loss carry forwards are not recognised in the statement of financial position. — Deferred tax assets...Annual report · 2025-12-31
Sale processThe company completed a business combination with Zelluna ASA (formerly Ultimovacs ASA), accounted for with Zelluna ASA as the accounting...Annual report · 2025-12-31
OtherGovernment grants (Research Council of Norway and Skattefunn) were received and recognised in the income statement. — The following gover...Annual report · 2025-12-31
OtherTotal cash outflows related to leases were MNOK 3.1 in 2024 and MNOK 2.4 in 2025. — The Company had total cash outflows related to leases...Annual report · 2025-12-31
OtherThe company applied for and was granted dispensation from the requirement to prepare the annual accounts in Norwegian. — Vi viser til der...Annual report · 2025-12-31
ZELLUNA ASA acquired 100.0 pctNew owner · 2025-12-31
GEVERAN TRADING COMPANY LTD exited (held 14.1 pct)Owner exit · 2025-12-31
MERRILL LYNCH, PIERCE, FENNER & SM exited (held 8.4 pct)Owner exit · 2025-12-31
RADFORSK INVESTERINGSSTIFTELSE exited (held 15.0 pct)Owner exit · 2025-12-31
BIRK VENTURE AS exited (held 9.6 pct)Owner exit · 2025-12-31
Skiwo · company_events
Job ads on NAV Arbeidsplassen12 MO
No job ads on record in the last 12 months.
NAV Arbeidsplassen · company_job_ad_months
LocationOslo
Oslo
municipality only · street address + coordinates not yet in Intelligo
Brreg · registered municipality